(0.05%) 5 102.32 points
(0.20%) 38 317 points
(0.07%) 15 939 points
(-1.28%) $82.78
(6.19%) $2.04
(-0.03%) $2 346.40
(-0.25%) $27.47
(3.81%) $957.20
(-0.19%) $0.933
(-0.30%) $10.99
(-0.51%) $0.796
(1.67%) $93.41
-0.81% INR 325.95
Live Chart Being Loaded With Signals
Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and ophthal/otologicals products, such as Renolen, Homide, Dexoren S, Zincoren, Otorex, Mofloren-D, and Mofloren LP...
Stats | |
---|---|
Dagens volum | 157 368 |
Gjennomsnittsvolum | 100 381 |
Markedsverdi | 30.05B |
EPS | INR0 ( 2024-01-23 ) |
Neste inntjeningsdato | ( INR2.80 ) 2024-05-21 |
Last Dividend | INR2.25 ( 2023-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 29.60 |
ATR14 | INR0.605 (0.19%) |
Volum Korrelasjon
Indoco Remedies Limited Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
ICICIGI.NS | 0.898 |
RADIOCITY.NS | 0.889 |
INSECTICID.NS | 0.883 |
INDUSTOWER.NS | 0.881 |
HDFCAMC.NS | 0.878 |
SAREGAMA.NS | 0.876 |
IDEA.NS | 0.874 |
PUNJABCHEM.NS | 0.869 |
SHOPERSTOP.NS | 0.866 |
TCIFINANCE.NS | 0.865 |
10 Mest negative korrelasjoner | |
---|---|
SICAGEN.NS | -0.883 |
SMLT.NS | -0.881 |
OIL.NS | -0.875 |
STAMPEDE.NS | -0.873 |
STERTOOLS.NS | -0.871 |
NEWGEN.NS | -0.871 |
KEERTI.NS | -0.869 |
SURYAROSNI.NS | -0.863 |
ROTO.NS | -0.862 |
PDSMFL.NS | -0.856 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Indoco Remedies Limited Korrelasjon - Valuta/Råvare
Indoco Remedies Limited Økonomi
Annual | 2022 |
Omsetning: | INR16.40B |
Bruttogevinst: | INR11.19B (68.21 %) |
EPS: | INR15.44 |
FY | 2022 |
Omsetning: | INR16.40B |
Bruttogevinst: | INR11.19B (68.21 %) |
EPS: | INR15.44 |
FY | 2022 |
Omsetning: | INR15.04B |
Bruttogevinst: | INR10.40B (69.16 %) |
EPS: | INR16.80 |
FY | 2021 |
Omsetning: | INR12.19B |
Bruttogevinst: | INR8.59B (70.49 %) |
EPS: | INR10.10 |
Financial Reports:
No articles found.
Indoco Remedies Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0.750 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR2.25 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.667 | 2005-09-15 |
Last Dividend | INR2.25 | 2023-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | INR20.23 | -- |
Avg. Dividend % Per Year | 0.26% | -- |
Score | 1.79 | -- |
Div. Sustainability Score | 2.93 | |
Div.Growth Potential Score | 3.59 | |
Div. Directional Score | 3.26 | -- |
Year | Amount | Yield |
---|---|---|
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.000 | 0.52% |
2019 | INR0.300 | 0.14% |
2020 | INR0.300 | 0.16% |
2021 | INR1.500 | 0.49% |
2022 | INR0.750 | 0.17% |
2023 | INR2.25 | 0.55% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TORNTPHARM.NS | Dividend Junior | 2023-06-23 | Annually | 22 | 0.85% | |
PGHH.NS | Dividend Knight | 2023-11-16 | Semi-Annually | 21 | 0.86% | |
JBMA.NS | Dividend Junior | 2023-09-08 | Annually | 20 | 0.32% | |
DECCANCE.NS | Dividend Junior | 2023-09-22 | Annually | 17 | 0.64% | |
SKFINDIA.NS | Dividend Junior | 2023-06-28 | Annually | 22 | 0.93% | |
METROBRAND.NS | Dividend Junior | 2023-08-31 | Semi-Annually | 3 | 0.18% | |
HAL.NS | Dividend Knight | 2023-08-24 | Semi-Annually | 6 | 4.33% | |
BCG.NS | Ex Dividend Junior | 2023-09-28 | Sporadic | 9 | 0.20% | |
PSB.NS | No Dividend Player | 2023-07-04 | Sporadic | 14 | 0.77% | |
KCP.NS | Dividend Junior | 2023-08-10 | Annually | 23 | 0.55% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0571 | 1.500 | 8.86 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0969 | 1.500 | -0.0350 | -0.0524 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 5.33 | 1.000 | 9.14 | 9.14 | [3 - 30] |
operatingCashFlowPerShareTTM | 14.32 | 2.00 | 5.23 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 14.32 | 2.00 | 2.84 | 5.68 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.691 | 1.000 | 1.820 | 1.820 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.104 | 1.000 | 9.92 | 9.92 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.93 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 29.85 | 1.000 | 7.09 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0969 | 2.50 | -0.0225 | -0.0524 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 14.32 | 2.00 | 5.23 | 5.68 | [0 - 30] |
dividendYielPercentageTTM | 0.684 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 14.32 | 2.00 | 5.23 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.450 | 1.500 | -0.334 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0742 | 1.000 | -0.645 | 0 | [0.1 - 0.5] |
Total Score | 3.59 |
Indoco Remedies Limited
Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and ophthal/otologicals products, such as Renolen, Homide, Dexoren S, Zincoren, Otorex, Mofloren-D, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Cal Aid, SM Fibro, MCBM DHA, and Apispur; urology products, such as Carmicide and Cital; Cloben G and Scabex for dermatology; ATM for anti-infectives; Hemsyl for blood related; MCBM 69 and D Chiro for gynecological; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers services that include architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company serves general practitioners, pediatricians, consultant physicians, dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.